Trial record 1 of 1409 for:    parkinson's disease[ALL-FIELDS]
Previous Study | Return to List | Next Study

GM1 Ganglioside Effects on Parkinson's Disease

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT00037830
First received: May 22, 2002
Last updated: December 18, 2012
Last verified: December 2012
  Purpose

The purpose of this trial is to examine the short term effects (24 Weeks) of GM1 on Parkinson's disease (PD) symptoms, as well as the effects of long-term treatment (120 Weeks) with GM1 on disease progression, and to examine the extent to which GM1 treatment influences the underlying disease process in PD.


Condition Intervention Phase
Parkinson Disease
Drug: GM1 ganglioside
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication

Resource links provided by NLM:


Further study details as provided by Thomas Jefferson University:

Primary Outcome Measures:
  • Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.

  • Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Scores From Baseline to Week 120 Assessed Off Medication. [ Time Frame: Baseline to Week 120 ] [ Designated as safety issue: No ]
    The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.


Secondary Outcome Measures:
  • Change From Baseline to Week 24 in Total Unified Parkinson's Disease Rating Scale (UPDRS)Score Assessed Off Medication [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The total Unified Parkinson's Disease Rating Scale (UPDRS) score is derived from Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Part I assesses 4 functions; Part II assesses 13 activities of daily living; Part III assesses 14 motor symptoms. Each item is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 176. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.

  • Change in Total UPDRS Score From Baseline to Week 120 Assessed Off Medication [ Time Frame: Baseline to Week 120 ] [ Designated as safety issue: No ]
    The total Unified Parkinson's Disease Rating Scale (UPDRS) score is derived from Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Part I assesses 4 functions; Part II assesses 13 activities of daily living; Part III assesses 14 motor symptoms. Each item is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 176. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.

  • Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.

  • Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 48 Assessed Off Medication. [ Time Frame: Baseline to Week 48 ] [ Designated as safety issue: No ]
    The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.

  • Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 72 Assessed Off Medication. [ Time Frame: Baseline to Week 72 ] [ Designated as safety issue: No ]
    The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.

  • Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 96 Assessed Off Medication. [ Time Frame: Baseline to Week 96 ] [ Designated as safety issue: No ]
    The Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) motor scores assess 14 symptoms some of which separately assess symptoms in different body parts (e.g. right arm, left arm, right leg, left leg) and each symptom is rated on a scale from 0 (normal) to 4 (severe). The minimum total score possible is 0 and the maximum total score possible is 108. Each subject was independently rated by two observers at each study visit and a mean score was calculated for analysis.


Enrollment: 94
Study Start Date: November 1999
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Early-Start Group
Subjects were randomized to receive GM1 ganglioside for 24 weeks.
Drug: GM1 ganglioside
100 mg twice per day by subcutaneous injection
Other Name: Sygen
Placebo Comparator: Delayed-Start Group
Subjects were randomized to receive placebo for 24 weeks.
Drug: Placebo
Twice per day subcutaneous injection, equal volume as active drug
No Intervention: Comparison Group
A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.

Detailed Description:

The study is designed to further examine the extent to which GM1 ganglioside can improve symptoms, delay disease progression, and, perhaps, partially restore damaged brain cells in PD patients. GM1 ganglioside is a chemical that is normally found in the brain and is a normal part of the outer covering or membrane of nerve cells. This study will compare the effectiveness of GM1 to standard PD treatment. In addition to studying clinical measures of motor and cognitive functioning, the investigators will use PET (positron emission tomography) scanning to image the brain and the dopamine nerve endings in a subgroup of patients. Patients with mild to moderate idiopathic PD will be divided into 2 groups. One group will receive GM1 for 24 weeks and the other will receive placebo. At the end of this 24 week period, all patients will enter into a 96 week treatment period in which all patients will receive GM1.

In parallel, a group of standard-of-care patients with mild to moderate PD will be monitored over a 1 to 2 year period to assess the natural progression of PD. These patients will receive the same clinical evaluations as the treatment group subjects but they will not receive the experimental medication.

  Eligibility

Ages Eligible for Study:   39 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Btwn ages of 39-85 yrs old.
  • Females: at least 2 years post-menopausal; surgically sterile; or negative pregnancy test by quantitative serum ßHCG, & follow a reliable method of birth control for at least 2 months prior to entry, agree both to follow a reliable method of birth control, & to desist from breast feeding during, & for 1 month following, the study drug administration.
  • Dx of idiopathic PD 6 months prior to screening. The diagnosis requires: the presence of at least 2 of the 4 cardinal clinical manifestations of the disease, tremor, rigidity, bradykinesia, and disturbances of posture or gait, & at least 1 must be rigidity or bradykinesia.
  • Modified Hoehn and Yahr Staging between 1 and 3 as rated during an "off" period of at least 12 hours.
  • Unified Parkinson's Disease Rating Scale motor component score between 10 and 40 as rated during an "off" period of at least 12 hours and a score of 6 or greater during "on" period.
  • Antiparkinsonian treatments: stable treatment of l-dopa/carbidopa and/or dopamine agonist for at least 3 months prior to Screening.
  • Mini Mental State Exam score > 25.
  • Beck Depression Inventory score < 10.
  • Signed informed consent.

Exclusion criteria:

  • Abrupt onset of Parkinsonism.
  • Failure of Parkinsonian symptoms to have responded to l-dopa.
  • Motor symptoms (such as peak dose dyskinesias (UPDRS score > 3), & random on-off phenomenon, other than end-of-dose wearing-off, persistently fluctuating over a 6 month or longer period, in response to l-dopa.
  • Hx of findings of any movement disorder other than idiopathic PD.
  • A tremor score on the UPDRS motor scale of >5. Tremor score greater than 3 in an individual limb.
  • High-dose vitamin E therapy (more than 1000 I.U./day) any time during the period starting 3 months prior baseline.
  • Transient ischemic attack any time during the period starting 6 months prior baseline.
  • Hx of 2 or more strokes. Hx of any stroke that resulted in motor deficit, movement disorder, ataxia, cognitive impairment, or a hemi-inattention syndrome. Any stroke with residua at the time of, or within 6 months preceding, study entry.
  • Previous cerebral infarction, including lacunar infarction, in any area subserving motor function.
  • Binswanger's disease or hx of hypertensive encephalopathy.
  • Hx of encephalitis.
  • Hx of extended exposure to any known neurotoxin that may cause parkinsonism, or chronic or sufficient use or consumption of any non-medicinal substance that could cause risk of developing a movement disorder or disturbance of posture or gait.
  • Use of the following drugs within 6 months prior to screening: neuroleptics, metoclopramide, clozapine, flunarizine, alpha-methyldopa.
  • Patients actively taking a medicine that is known to compete with the imaging agent for binding sites on the dopamine terminals.
  • Hx of medication or drug use that may have caused atypical parkinsonism or history of Substance Use Disorder.
  • Hx of a metabolic disorder that resulted or could have resulted in movement disorder or disturbance of posture or gait.
  • Any disease or condition that resulted or could have resulted in a movement disorder or disturbance of posture or gait.
  • Hx of intracranial hemorrhage, intracranial neoplasm, significant head trauma with loss of consciousness >24 hrs or other structural brain disease.
  • Hx or clinical findings suggestive of progressive supranuclear palsy or multiple system atrophy.
  • Acquired cognitive impairment reasonably possibly due to any cause other than idiopathic PD.
  • Hx of a hereditary disorder associated with a movement disorder.
  • Normal or low pressure hydrocephalus.
  • Any ill-defined neuropathic disease, myelopathy, myopathy or other medical disorder or physical condition by history or clinical examination that could be expected to interfere with the diagnosis, treatment or assessment of PD, or with any of the study assessments.
  • Hx of Guillain-Barré syndrome, chronic idiopathic polyneuropathy, or relapsing polyneuropathy.
  • Hx of Axis I or Axis II major psychiatric disorder.
  • Significant cardiac, pulmonary, hepatic, gastrointestinal, or renal disease.
  • Any condition that could alter the distribution, accumulation, metabolism, or excretion of the study medication; or result in a life expectancy of less than 2 years.
  • Any primarily non-neurologic medical condition with a significant risk of secondarily causing neurologic dysfunction.
  • Myocardial infarction within 6 months prior to screening.
  • Presence of any medical condition or laboratory test abnormality or use of any licit or illicit substance which could cause unwarranted risk from participation in the study or result in worsening in the patient's medical condition during participation in study. Presence of any of the following laboratory test abnormalities are unwarranted risk: serum transaminase greater than twice the upper limit of normal;serum creatinine greater than 2.0 mg/dl in a man or greater than 1.7 mg/dl in a woman.
  • Hx of a life-threatening allergic or immune-mediated reaction.
  • Previous use of any ganglioside preparation.
  • Use of any experimental drug in the period starting 60 days before Baseline.
  • Hx of stereotaxic brain surgery for PD.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00037830

Locations
United States, Pennsylvania
Parkinson's Disease Research Unit, Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
Investigators
Principal Investigator: Jay S. Schneider, Ph.D. Parkinson's Disease Research Unit, Thomas Jefferson University
  More Information

No publications provided

Responsible Party: Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT00037830     History of Changes
Other Study ID Numbers: R01NS38681, R01NS038681
Study First Received: May 22, 2002
Results First Received: July 13, 2011
Last Updated: December 18, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Thomas Jefferson University:
Parkinson's disease
PD
GM1 Ganglioside
Sygen

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders

ClinicalTrials.gov processed this record on October 23, 2014